Aim To evaluate the late clinical efficacy and safety of anti-platelet therapy between ticagrelor and clopidogrel in unstable angina pectoris after selective PCI. Methods A total of 135 unstable angina pectoris after selective PCI was collected from Nanfang Hospital during January 2014 to December 2014. All patients were divided into ticagrelor group (n＝55) and clopidogrel group (n＝80) according to different anti-platelet therapeutic regimen. Follow-up period was at least 6 months. The endpoints included recurrence rate of angina pectoris, incidence of major adverse cardiac events (MACE), bleeding events and dyspnea. Results The average follow-up time in the ticagrelor group and the clopidogrel group was 13.0±3.2 months and 13.7±3.0 months. The recurrence rate of angina pectoris in the ticagrelor group [18.2% (10/55)] and clopidogrel group [27.5% (22/80)] showed no significant difference (P＝0.21). The incidence of MACE in the ticagrelor group (3/55) and clopidogrel group (6/80) showed no significant difference (P＝0.9).The incidence of bleeding events in the ticagrelor group (9/55) and clopidogrel group (17/80) showed no significant difference (P＝0.48). But the incidence of dyspnea in the ticagrelor group (9/55) and clopidogrel group (4/80) showed significant difference (P＝0.03). Conclusion The late clinical efficacy of anti-platelet therapy with ticagrelor was significant in unstable angina pectoris after selective PCI, and without increasing the risk of bleeding.